Please login to the form below

Not currently logged in
Email:
Password:

etelcalcetide

This page shows the latest etelcalcetide news and features for those working in and with pharma, biotech and healthcare.

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication

In draft guidance, the cost-effectiveness agency is backing use of Amgen's Parsabiv (etelcalcetide) for secondary hyperparathyroidism caused by CKD in patients on haemodialysis, but only for patients who cannot ... Given that etelcalcetide has similar

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics